How Much Did Astellas Pharma Raise?
Funding & Key Investors

Astellas Pharma has solidified its position as a global leader in the pharmaceutical sector, underscored by a robust history of capital accumulation. The firm has successfully secured a total funding amount of $212.5M, reflecting its sustained growth trajectory and market confidence. This financial foundation was most recently bolstered by a major strategic investment of $75M, which serves to accelerate the company's research and development initiatives on an international scale.

The organization's ability to attract significant backing from top-tier institutional investors highlights its operational excellence and the high-value potential of its drug development pipeline. By maintaining a disciplined approach to capital allocation, Astellas Pharma continues to navigate the complexities of the global healthcare market with precision and strategic foresight.

What is Astellas Pharma?

Astellas Pharma
ManufacturingPharmaceuticals

Headquartered in Tokyo, Japan, Astellas Pharma is a premier pharmaceutical entity dedicated to the manufacturing, marketing, import, and export of innovative medical solutions. The company operates at the intersection of biotechnology and large-scale pharmaceutical production, focusing on therapeutic areas that address significant unmet medical needs. Through its commitment to scientific rigor and commercial scalability, Astellas Pharma has established a formidable presence in the global life sciences industry, leveraging its extensive distribution networks to deliver life-saving treatments to patients worldwide.

The company's market position is defined by its ability to integrate advanced research with efficient supply chain management. By prioritizing high-impact therapeutic development, Astellas Pharma remains a critical player in the evolving landscape of modern medicine, consistently demonstrating the capacity to scale operations while maintaining stringent regulatory and quality standards.

How much funding has Astellas Pharma raised?

Astellas Pharma has raised a total of $212.5M across 4 funding rounds:

2013

Series A

$30M

2014

Series B

$42.5M

2015

Series C

$65M

2016

Stock Offering

$75M

Series A (2013): $30M with participation from Versant Ventures, 5AM Ventures, and OrbiMed

Series B (2014): $42.5M led by Deerfield Management, Venrock Associates, 5AM Ventures, Sofinnova Ventures, Versant Ventures, and OrbiMed

Series C (2015): $65M supported by Sofinnova Ventures, OrbiMed, Cowen, Deerfield Management, Venrock Associates, Foresite Capital, Cormorant Asset Management, 5AM Ventures, Redmile Group, Versant Ventures, and RA Capital Management

Stock Issuance/Offering (2016): $75M, investors not publicly disclosed

Key Investors in Astellas Pharma

Versant Ventures

A prominent healthcare-focused venture capital firm that invests in early-stage companies to build transformative medical businesses.

OrbiMed

A leading global investment firm dedicated exclusively to the healthcare sector, providing capital across the entire spectrum of life sciences.

5AM Ventures

A venture capital firm specializing in the creation and investment of early-stage life science companies with a focus on breakthrough technologies.

What's next for Astellas Pharma?

Looking ahead, the recent infusion of capital positions Astellas Pharma to further expand its clinical trial capabilities and enhance its portfolio of next-generation therapeutics. The strategic deployment of these funds will likely focus on accelerating the commercialization of late-stage assets and exploring potential partnerships to bolster its competitive advantage in the global market.

As the company enters this new phase of growth, stakeholders can expect a continued emphasis on operational efficiency and the pursuit of breakthrough innovations. By leveraging its strong financial backing, Astellas Pharma is well-equipped to address the challenges of an increasingly complex regulatory environment while driving long-term value for its investors and patients alike.

See full Astellas Pharma company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Manufacturing industry

Industrial Machinery & EquipmentManufacturing
ElectronicsManufacturing
ManufacturingWatches & JewelryJewelry & Watch RetailRetail
Food & BeverageManufacturingHospitalityRestaurant ReservationsRetailGrocery Retail

Frequently Asked Questions Regarding Astellas Pharma Financial Insights

What are the most recent funding rounds that Astellas Pharma has completed, and what were the funding rounds?
Astellas Pharma has recently completed 3 funding rounds: Stock Offering on Jul 20, 2016, Series C on Oct 13, 2015, Series B on Dec 2, 2014.
What is the total amount of funding Astellas Pharma has raised to date?
Astellas Pharma has raised a total of $212.5M in funding to date.
How many funding rounds has Astellas Pharma completed?
Astellas Pharma has completed 3 funding rounds.
How much funding did Astellas Pharma raise in its most recent funding round?
Astellas Pharma raised $75M in its most recent funding round.
Which was the largest funding round in Astellas Pharma's history?
The largest funding round in Astellas Pharma's history was $75M.
See more information about Astellas Pharma